Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE:LLY) announced FDA approval of Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related conditions, available by prescription immediately and shipping from April 6, 2026. In ATTAIN-1, the highest dose produced an average 27.3 lb (12.4%) weight loss versus 2.2 lb (0.9%) placebo; overall trial participants lost 25 lb (11.1%) versus 5.3 lb (2.1%) placebo.
Foundayo will be distributed via LillyDirect with commercial copays from $25/month and self-pay starting at $149/month; Medicare Part D access may begin July 1, 2026. Safety warnings include potential thyroid tumors and common GI side effects.
Eli Lilly (NYSE: LLY) agreed to acquire Centessa Pharmaceuticals for $38.00 cash per share plus one CVR, yielding up to $47.00 per share if regulatory milestones are met. The upfront consideration implies an aggregate equity value of ~$6.3 billion and the CVR adds potential ~$1.5 billion.
The deal expands Lilly's neuroscience footprint into sleep medicine by adding Centessa's OX2R agonist portfolio, including lead candidate cleminorexton (Phase 2a) targeting narcolepsy and idiopathic hypersomnia. Closing is expected in Q3 2026, subject to shareholder, High Court and regulatory approvals.
Eli Lilly (NYSE: LLY) reported Phase 3b TOGETHER-PsA results showing that concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) was superior to Taltz alone at Week 36 across the primary endpoint and all key secondaries.
The combination delivered ACR50 plus ≥10% weight reduction in 31.7% versus 0.8%, higher ACR50 (33.5% vs 20.4%), greater ≥10% weight loss (84.5% vs 4.5%) and improved MDA, hsCRP, HAQ-DI, FACIT-Fatigue and SF-36 MCS.
Lilly (NYSE: LLY) reported interim ADlong Phase 3b data on March 27, 2026 showing long-term durability for EBGLYSS (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. Observed results up to four years: EASI-75 94%, EASI-90 75%, IGA 0/1 68%, Pruritus NRS ≤4 78%.
Most patients (77%) received monotherapy, 80% achieved outcomes without topical corticosteroids, and monthly maintenance dosing produced sustained control; safety in year one was consistent with known profile.
Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for retatrutide in TRANSCEND-T2D-1 on March 19, 2026. At 40 weeks, retatrutide produced up to 2.0% A1C reduction and up to 16.8% weight loss (36.6 lbs) versus placebo, meeting primary and all key secondary endpoints.
Improvements were seen across doses (4 mg, 9 mg, 12 mg) and cardiovascular risk markers; common adverse events were nausea, diarrhea and vomiting, mostly during dose escalation.
Lilly (NYSE: LLY) reported positive topline Phase 3 ADorable-1 results for EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis on March 16, 2026. At Week 16, EBGLYSS achieved EASI-75 63%, IGA 0,1 44%, EASI-90 39% and Pruritus NRS ≥4 improvement 35%. Safety was consistent with adult/adolescent studies, with no new signals and no injection site pain reported. Lilly plans regulatory submissions for potential pediatric label updates; the ADorable program and a 52-week extension continue.
Eli Lilly (NYSE: LLY) launched the Lilly Employer Connect platform on March 5, 2026 to expand employer-sponsored access to obesity medicines. The program starts with over 15 independent program administrators and offers Zepbound KwikPen at a discounted price of $449 per device across all doses to participating network pharmacies.
The platform enables flexible cost-share models and nationwide pharmacy support, while preserving provider and patient choice. Clinical data cited include SURMOUNT-1 (15 mg: 20.9% mean weight loss at 72 weeks vs 3.1% placebo) and SURMOUNT-5 open-label comparisons.
Eli Lilly (NYSE: LLY) announced a positive CHMP opinion recommending Olumiant (baricitinib) for adolescents ages 12 to <18 with severe alopecia areata. The recommendation is based on Phase 3 BRAVE-AA-PEDS results showing 42.4% achieved ≥80% scalp hair coverage at 36 weeks (4 mg).
The opinion moves to the European Commission for final action, expected in one to two months; a U.S. decision is expected in the second half of 2026.
Chondrosarcoma market (covering 7MM) is forecast to grow from 2026–2036 as diagnosis improves and new therapies advance. Approximately 1,400 incident US cases were reported in 2024–25. Emerging drugs include Ozekibart (INBRX-109), TIBSOVO (ivosidenib), and LY3410738 (LLY), with planned regulatory filings and ongoing pivotal trials.
The pipeline remains limited; however, Fast Track designations, positive Phase II topline data, a planned BLA in Q2 2026, and a Phase III primary completion expected Feb 2028 could reshape care for unresectable and metastatic disease.
Eli Lilly (NYSE: LLY) reported 52-week ACHIEVE-3 results showing oral orforglipron outperformed oral semaglutide on A1C and weight. At 36 mg, orforglipron reduced A1C by 2.2% vs 1.4% and produced 9.2% weight loss (19.7 lbs) vs 5.3% (11.0 lbs).
Orforglipron improved multiple cardiovascular risk factors, had higher treatment discontinuation rates, and has regulatory submissions in >40 countries with potential U.S. obesity action in Q2 2026.